1. Concurrent EGFR and PIK3CA mutations in non-small-cell lung cancer;Kapoor;Cancer Res Stat Treat,2021
2. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling;Chaft;Mol Cancer Ther,2012
3. Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors;Qiu;Am J Cancer Res,2021
4. Analysis Identifies Frequency of PI3K Pathway Alterations in Patients with NSCLC – The ASCO Post. Available from: https://ascopost.com/news/march-2021/analysis-identifies-frequency-of-pi3k-pathway-alterations-in-patients-with-nsclc/. [Last accessed on 2021 Oct 29].
5. Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management;Rajendra;Cancer Res Stat Treat,2019